NO20045037L - Fremgangsmate for fremstilling av atorvastatin-kalsium i amorf form - Google Patents

Fremgangsmate for fremstilling av atorvastatin-kalsium i amorf form

Info

Publication number
NO20045037L
NO20045037L NO20045037A NO20045037A NO20045037L NO 20045037 L NO20045037 L NO 20045037L NO 20045037 A NO20045037 A NO 20045037A NO 20045037 A NO20045037 A NO 20045037A NO 20045037 L NO20045037 L NO 20045037L
Authority
NO
Norway
Prior art keywords
preparation
amorphous form
atorvastatin calcium
atorvastatin
calcium
Prior art date
Application number
NO20045037A
Other languages
English (en)
Other versions
NO20045037D0 (no
NO330092B1 (no
Inventor
Yatendra Kumar
Swargam Sathyanarayana
Saridi Madhava Dileep Kumar
Original Assignee
Ranbaxy Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Lab Ltd filed Critical Ranbaxy Lab Ltd
Publication of NO20045037D0 publication Critical patent/NO20045037D0/no
Publication of NO20045037L publication Critical patent/NO20045037L/no
Publication of NO330092B1 publication Critical patent/NO330092B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pyrrole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20045037A 2004-03-17 2004-11-19 Fremgangsmate for fremstilling av atorvastatin-kalsium i amorf form NO330092B1 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN491DE2004 2004-03-17

Publications (3)

Publication Number Publication Date
NO20045037D0 NO20045037D0 (no) 2004-11-19
NO20045037L true NO20045037L (no) 2005-09-19
NO330092B1 NO330092B1 (no) 2011-02-14

Family

ID=33516010

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20045037A NO330092B1 (no) 2004-03-17 2004-11-19 Fremgangsmate for fremstilling av atorvastatin-kalsium i amorf form

Country Status (17)

Country Link
US (1) US7994343B2 (no)
EP (3) EP1577297A1 (no)
CN (2) CN1942439B (no)
AR (1) AR048271A1 (no)
AT (1) ATE545629T1 (no)
AU (2) AU2004317570B2 (no)
CA (3) CA2560252C (no)
CY (1) CY1112583T1 (no)
DK (1) DK1727795T3 (no)
ES (1) ES2381473T3 (no)
FI (1) FI120344B (no)
MY (1) MY147435A (no)
NO (1) NO330092B1 (no)
PL (1) PL1727795T3 (no)
PT (1) PT1727795E (no)
SI (1) SI1727795T1 (no)
WO (1) WO2005092852A1 (no)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1727795T1 (sl) * 2004-03-17 2012-05-31 Ranbaxy Lab Ltd Postopek za pripravo atorvastatin kalcija v amorfni obliki
EP1771455B1 (en) * 2004-07-16 2016-05-11 LEK Pharmaceuticals d.d. Oxidative degradation products of atorvastatin calcium
EP1784389A4 (en) * 2004-08-27 2009-03-25 Biocon Ltd PROCESS FOR THE PREPARATION OF AMORPHIC ATORVASTATIN CALCIUM
GB2424880A (en) * 2005-04-06 2006-10-11 Generics Crystalline forms of atorvastatin sodium, processes for their preparation and their use in inhibiting HMG-CoA reductase
GB0613567D0 (en) * 2006-07-07 2006-08-16 Arrow Int Ltd Crystalline sodium atorvastatin
CA2619040C (en) 2005-08-15 2015-02-10 Arrow International Limited Crystalline and amorphous sodium atorvastatin
GB0613566D0 (en) * 2006-07-07 2006-08-16 Arrow Int Ltd Crystalline sodium atorvastatin
CA2619486C (en) 2005-08-15 2015-05-12 Arrow International Limited Crystalline and amorphous sodium atorvastatin
ES2270722B1 (es) * 2005-09-15 2008-03-01 Ercros Industrial, S.A. Procedimiento para la obtencion de atorvastatina calcica amorfa.
GB0523637D0 (en) * 2005-11-21 2005-12-28 Avecia Pharmaceuticals Ltd Process and compounds
WO2007099552A2 (en) * 2006-03-02 2007-09-07 Matrix Labaratories Ltd Novel crystalline form of atovastatin hemi-magnesium
SI22255A (sl) * 2006-04-14 2007-10-31 Krka, Tovarna Zdravil, D.D., Novo Mesto Novi polimorfi statinovih soli in njihova uporabav farmacevtskih formulacijah
CN101205209B (zh) * 2007-12-25 2010-06-02 浙江新东港药业股份有限公司 一种阿伐他汀中间体的精制方法
EP2075246A1 (en) * 2007-12-27 2009-07-01 M. J. Institute of Research A process for preparation of amorphous form of atorvastatin hemi-calcium salt
CN101468963B (zh) * 2007-12-28 2012-09-19 石药集团中奇制药技术（石家庄）有限公司 一种无定形阿伐他汀钙的制备方法
KR100850558B1 (ko) * 2008-01-02 2008-08-06 조동옥 아토르바스타틴의 효율적인 제조방법
CN101560177B (zh) * 2008-04-16 2012-10-03 北京万全阳光医学技术有限公司 一种阿托伐他汀钙的制备方法
CN101429195B (zh) * 2008-11-03 2010-12-15 华东师范大学 一种高纯度阿托伐他汀重要合成中间体的制备方法
US8115015B2 (en) 2009-01-26 2012-02-14 Cadila Healthcare Limited Process for the preparation of amorphous atorvastatin calcium
US20130041162A1 (en) * 2010-04-19 2013-02-14 Dsm Sinochem Pharmaceuticals Netherlands B.V. Production of atorvastatin low in ether impurities
CN102127060B (zh) * 2010-12-17 2013-12-04 蚌埠丰原医药科技发展有限公司 一种阿托伐他汀钙中间体的制备方法
CN102070504A (zh) * 2010-12-23 2011-05-25 蚌埠丰原医药科技发展有限公司 阿托伐他汀钠的制备方法
CN102070505B (zh) * 2011-01-28 2012-01-11 海南美大制药有限公司 阿托伐他汀钙化合物及其新制法
CN103483238B (zh) * 2013-08-20 2014-12-31 蚌埠丰原医药科技发展有限公司 阿托伐他汀钙三水合物的制备方法
CN104945300B (zh) * 2015-06-17 2017-05-10 北京嘉林药业股份有限公司 一种ⅰ型阿托伐他汀钙的纯化方法
WO2017060885A1 (en) * 2015-10-09 2017-04-13 Laurus Labs Private Limited An improved process for preparation of atorvastatin or pharmaceutically acceptable salts thereof
CN106478591B (zh) * 2016-09-30 2018-11-13 北京嘉林药业股份有限公司 一种阿托伐他汀缩合物中间体的拆分方法
CN106432033B (zh) * 2016-10-21 2018-07-27 江苏阿尔法药业有限公司 一种无定形阿托伐他汀钙的制备方法
CN108033899B (zh) * 2017-12-06 2020-04-10 浙江科技学院 一种(r)-6-氰基-5-羟基-3-羰基己酸叔丁酯的制备方法
CN109232355A (zh) * 2018-10-09 2019-01-18 河南师范大学 一种有效去除阿托伐他汀钙粗品中杂质阿托伐他汀缩合物的方法
CN109280024A (zh) * 2018-10-09 2019-01-29 河南师范大学 一种高纯度阿托伐他汀叔丁酯的制备方法
CN110563628B (zh) * 2019-08-26 2022-04-05 北京嘉林药业股份有限公司 一种双釜制备高纯度和单分散i晶型阿托伐他汀钙的结晶方法
CN110776451B (zh) * 2020-01-02 2020-05-22 湖南迪诺制药股份有限公司 一种i晶型阿托伐他汀钙的制备方法
CN113695307B (zh) * 2020-05-20 2022-12-02 天津嘉林科医有限公司 一种盛放阿托伐他汀钙的玻璃器皿的清洗方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5097045A (en) 1989-02-01 1992-03-17 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5245047A (en) 1988-02-22 1993-09-14 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5003080A (en) 1988-02-22 1991-03-26 Warner-Lambert Company Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis
US5124482A (en) 1988-02-22 1992-06-23 Warner-Lambert Company Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis
US5216174A (en) 1988-02-22 1993-06-01 Warner-Lambert Co. Process for trans-6-[12-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5149837A (en) 1988-02-22 1992-09-22 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5248793A (en) 1990-10-17 1993-09-28 Warner-Lambert Company Process for the synthesis of (4R-cis)-1,1-dimethylethyl 6-iodomethyl or 6-(phenyl-substituted)sulfonyloxymethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5103024A (en) 1990-10-17 1992-04-07 Warner-Lambert Company Process for the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5155251A (en) 1991-10-11 1992-10-13 Warner-Lambert Company Process for the synthesis of (5R)-1,1-dimethylethyl-6-cyano-5-hydroxy-3-oxo-hexanoate
WO1994016693A1 (en) 1993-01-19 1994-08-04 Warner-Lambert Company Stable oral ci-981 formulation and process of preparing same
US5298627A (en) 1993-03-03 1994-03-29 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
HRP960312B1 (en) * 1995-07-17 2001-10-31 Warner Lambert Co NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS /R-(R*, R*)/-2-(4-FLUOROPHENYL)-"beta", "delta"-DIHYDROXY-5-PHENYL-4-/(PHENYLAMINO)CARBONYL/-1H-PYRROLE -1-HEPTANOIC ACID CALCIUM SALT (2 : 1)
IL122118A (en) 1995-07-17 1999-07-14 Warner Lambert Co Crystalline form I atorvastatin pharmaceutical compositions containing it and process for its preparation
IN191236B (no) 1999-05-25 2003-10-11 Ranbaxy Lab Ltd
US6646133B1 (en) * 2000-10-17 2003-11-11 Egis Gyogyszergyar Rt. Process for the preparation of amorphous atorvastatin calcium
HU226640B1 (en) 1999-10-18 2009-05-28 Egis Gyogyszergyar Nyilvanosan Process for producing amorphous atorvastatin calcium salt
SI20425A (sl) * 1999-12-10 2001-06-30 LEK tovarna farmacevtskih in kemi�nih izdelkov d.d. Priprava amorfnega atorvastatina
SK16982002A3 (sk) 2000-06-09 2003-04-01 Lek Pharmaceuticals D. D. Stabilizovaná farmaceuticky účinná kompozícia a liečivý prípravok túto kompozíciu obsahujúci
US6605636B2 (en) 2000-11-03 2003-08-12 Teva Pharmaceutical Industries Ltd. Atorvastatin hemi-calcium form VII
IL156055A0 (en) 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
WO2002057225A2 (en) 2000-12-18 2002-07-25 Merck & Co., Inc. Thrombin inhibitors
CN1273449C (zh) 2000-12-27 2006-09-06 特瓦制药工业有限公司 阿伐他汀的晶型
WO2002057228A1 (en) 2001-01-17 2002-07-25 Biocon India Limited Atorvastatin calcium
SI20814A (sl) 2001-01-23 2002-08-31 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Priprava amorfnega atorvastatina
IN190564B (no) 2001-04-11 2003-08-09 Cadila Heathcare Ltd
MXPA03010266A (es) 2001-06-29 2004-03-10 Warner Lambert Co Formas cristalinas de la sal de calcio del acido [r-(r*, r*)]-2 -(4-fluorofenil)-¦, d-dihidroxi-5 -(1-metiletil)-3 -fenil-4- [(fenilamino) carbonil ]-1h- pirrol-1-heptanoico (2:1) (atorvastatin).
JP2005500351A (ja) 2001-07-30 2005-01-06 ドクター・レディーズ・ラボラトリーズ・リミテッド 結晶形態ｖｉおよびｖｉｉのアトルバスタチンカルシウム
AU2001284385A1 (en) 2001-08-31 2003-03-10 Morepen Laboratories Ltd. An improved process for the preparation of amorphous atorvastatin calcium salt (2:1)
CZ296967B6 (cs) * 2002-02-01 2006-08-16 Zentiva, A.S. Zpusob výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu)
ES2338530T3 (es) 2002-03-18 2010-05-10 Biocon Limited Inhibidores de hmg-coa reductasa amorfos del tamaño de particulas deseado.
WO2003099785A1 (en) 2002-05-28 2003-12-04 Cadila Healthcare Limited Process for the preparation of amorphous atorvastatin calcium
SI21302A (sl) 2002-10-11 2004-04-30 LEK farmacevtska dru�ba d.d. Stabiliziran farmacevtski izdelek z amorfno aktivno učinkovino
HU227041B1 (en) 2003-03-24 2010-05-28 Richter Gedeon Nyrt Process for the synthesis of amorphous atorvastatin calcium
SI1727795T1 (sl) * 2004-03-17 2012-05-31 Ranbaxy Lab Ltd Postopek za pripravo atorvastatin kalcija v amorfni obliki
TWI321132B (en) 2004-09-28 2010-03-01 Teva Pharma Process for preparing forms of atorvastatin calcium substantially free of impurities

Also Published As

Publication number Publication date
AU2004317570A1 (en) 2005-10-06
CA2560252C (en) 2009-08-04
WO2005092852A1 (en) 2005-10-06
EP1577297A1 (en) 2005-09-21
SI1727795T1 (sl) 2012-05-31
EP1727795A1 (en) 2006-12-06
AR048271A1 (es) 2006-04-12
CN1942439B (zh) 2011-12-21
EP1727795B1 (en) 2012-02-15
NO20045037D0 (no) 2004-11-19
EP1659110A1 (en) 2006-05-24
MY147435A (en) 2012-12-14
DK1727795T3 (da) 2012-04-16
CA2627940A1 (en) 2005-10-06
CA2560252A1 (en) 2005-10-06
AU2004317570B2 (en) 2011-01-06
CY1112583T1 (el) 2016-02-10
ES2381473T3 (es) 2012-05-28
ATE545629T1 (de) 2012-03-15
CA2666359A1 (en) 2005-10-06
CN1946688A (zh) 2007-04-11
US20100197941A1 (en) 2010-08-05
FI20041489A (fi) 2006-07-20
US7994343B2 (en) 2011-08-09
FI20041489A0 (fi) 2004-11-19
NO330092B1 (no) 2011-02-14
AU2010249166A1 (en) 2010-12-23
FI120344B (fi) 2009-09-30
CN1942439A (zh) 2007-04-04
PL1727795T3 (pl) 2012-06-29
PT1727795E (pt) 2012-04-11
AU2010249166B2 (en) 2012-02-09

Similar Documents

Publication Publication Date Title
NO20045037L (no) Fremgangsmate for fremstilling av atorvastatin-kalsium i amorf form
NO20070753L (no) Fremgangsmåte for fremstilling av dihydropteridinoner
NO20076030L (no) Fremgangsmåte for fremstilling av hydroklorsilaner
EP1984386A4 (en) METHODS FOR SYNTHESIZING TWO OR MORE DICARBA BRIDGES IN ORGANIC COMPOUNDS
IL187578A0 (en) Process for preparing pure amorphous rosuvastatin calcium
IL192241A (en) A process for making 4 - (benzimidazolylmethylamino) - benzamides and their salts
DE602005017099D1 (de) Verfahren zur Herstellung von amorphem Cefuroximaxetil
ZA200702965B (en) Process for forming amorphous atorvastatin
EP1793815A4 (en) AMORPHES ATORVASTATINCALCIUM
EP1984385A4 (en) PROCESS FOR SYNTHESIS OF DICARBABRICES IN ORGANIC COMPOUNDS
FI20080427A (fi) Menetelmä saostetun kalsiumkarbonaatin valmistamiseksi
AU2006264650A8 (en) Zofenopril calcium in polymorph form C
DE602005023870D1 (de) Vorrichtungen zur herstellung von objekten
SI1753720T1 (sl) Postopek za pripravo perindoprila in njegovih soli
NO20082458L (no) Fremgangsmåter for fremstilling av cyklopropyl-amidderivat
HU0300761D0 (en) Process for the production of amorphous atorvastatin calcium
ZA200608632B (en) Process for forming amorphous atorvastatin calcium
FR2894958B1 (fr) Procede de preparation de difluoroethanol
IL194876A0 (en) Crystalline form of atorvastatin calcium stable after storage
IL186499A (en) Processes for the preparation of a crystalline form of atorostatin mycelium
DE112006001001A5 (de) Verfahren zur Herstellung von Tetrahydropyran-Derivaten
HU0401379D0 (en) Process for the preparation of risperidon
FI20065594L (fi) Menetelmä amorfisessa muodossa olevan atorvastatiinikalsiumin valmistamiseksi
FR2871801B1 (fr) Procede de preparation d'arylboronates cycliques
HU0401374D0 (en) Composition and process for producing retard fertilizers

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees